Bukwang Pharmaceutical Co., Ltd. (KRX: 003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,745.00
-65.00 (-1.35%)
Dec 19, 2024, 3:30 PM KST

Bukwang Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
138,927125,928190,909182,491169,660168,194
Upgrade
Other Revenue
-0-0-0--0-
Upgrade
Revenue
138,927125,928190,909182,491169,660168,194
Upgrade
Revenue Growth (YoY)
-14.45%-34.04%4.61%7.56%0.87%-13.40%
Upgrade
Cost of Revenue
79,65279,012111,763106,94298,31984,842
Upgrade
Gross Profit
59,27546,91679,14775,55071,34183,352
Upgrade
Selling, General & Admin
44,96951,27449,79743,47745,37353,067
Upgrade
Research & Development
30,52734,55124,27422,46518,03217,312
Upgrade
Other Operating Expenses
2,7552,0781,3451,3171,5631,242
Upgrade
Operating Expenses
75,32284,41379,37769,92867,31373,814
Upgrade
Operating Income
-16,047-37,497-230.645,6224,0289,537
Upgrade
Interest Expense
-3,808-3,808-1,760-1,408-1,515-90.85
Upgrade
Interest & Investment Income
3,0803,0801,440268.161,3132,055
Upgrade
Earnings From Equity Investments
-498.26-1,50158.57-1,361-2,838-783.95
Upgrade
Currency Exchange Gain (Loss)
-177.44-177.4488.47322.31-2,10576.4
Upgrade
Other Non Operating Income (Expenses)
496.78867.73-113.7333.63-401.19-368.31
Upgrade
EBT Excluding Unusual Items
-16,954-39,036-517.653,477-1,51810,425
Upgrade
Gain (Loss) on Sale of Investments
-564.4-564.4-567.4790.53-3,297-11,791
Upgrade
Gain (Loss) on Sale of Assets
30.6430.6452.25220.0554.253.42
Upgrade
Asset Writedown
-----3,539-
Upgrade
Pretax Income
-17,488-39,569-1,0333,787-8,300-1,362
Upgrade
Income Tax Expense
-497.99-5,1633,2166,5841,8056,073
Upgrade
Earnings From Continuing Operations
-16,990-34,407-4,249-2,797-10,105-7,435
Upgrade
Minority Interest in Earnings
1,7043,0771,7741,8802,90222.48
Upgrade
Net Income
-15,285-31,330-2,475-916.62-7,203-7,412
Upgrade
Net Income to Common
-15,285-31,330-2,475-916.62-7,203-7,412
Upgrade
Shares Outstanding (Basic)
686868686972
Upgrade
Shares Outstanding (Diluted)
686868686972
Upgrade
Shares Change (YoY)
0.44%--0.01%-0.25%-4.24%-1.37%
Upgrade
EPS (Basic)
-223.26-457.67-36.15-13.39-104.95-103.43
Upgrade
EPS (Diluted)
-223.59-458.00-36.15-13.39-105.00-103.64
Upgrade
Free Cash Flow
38,891-12,19612,16325,740-1,194-26,945
Upgrade
Free Cash Flow Per Share
568.06-178.17177.68375.98-17.40-375.98
Upgrade
Gross Margin
42.67%37.26%41.46%41.40%42.05%49.56%
Upgrade
Operating Margin
-11.55%-29.78%-0.12%3.08%2.37%5.67%
Upgrade
Profit Margin
-11.00%-24.88%-1.30%-0.50%-4.25%-4.41%
Upgrade
Free Cash Flow Margin
27.99%-9.69%6.37%14.10%-0.70%-16.02%
Upgrade
EBITDA
-12,036-33,2044,88610,46510,18615,377
Upgrade
EBITDA Margin
-8.66%-26.37%2.56%5.73%6.00%9.14%
Upgrade
D&A For EBITDA
4,0114,2925,1174,8436,1585,840
Upgrade
EBIT
-16,047-37,497-230.645,6224,0289,537
Upgrade
EBIT Margin
-11.55%-29.78%-0.12%3.08%2.37%5.67%
Upgrade
Effective Tax Rate
---173.85%--
Upgrade
Advertising Expenses
-12,76412,1816,6228,78413,021
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.